期刊
VIRUSES-BASEL
卷 13, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/v13040624
关键词
Influenza virus; hemagglutinin; neuraminidase; antiviral resistance; antiviral
类别
资金
- Open Project funding mechanism of the State Key Laboratory of Respiratory Diseases
Hemagglutinin and neuraminidase are critical parts of influenza viruses, serving as targets for immune response and antiviral drugs. Neuraminidase inhibitors like oseltamivir are commonly used against influenza, while antivirals targeting hemagglutinin are newer with a higher resistance threshold.
Hemagglutinin and neuraminidase, which constitute the glycoprotein spikes expressed on the surface of influenza A and B viruses, are the most exposed parts of the virus and play critical roles in the viral lifecycle. As such, they make prominent targets for the immune response and antiviral drugs. Neuraminidase inhibitors, particularly oseltamivir, constitute the most commonly used antivirals against influenza viruses, and they have proved their clinical utility against seasonal and emerging influenza viruses. However, the emergence of resistant strains remains a constant threat and consideration. Antivirals targeting the hemagglutinin protein are relatively new and have yet to gain global use but are proving to be effective additions to the antiviral repertoire, with a relatively high threshold for the emergence of resistance. Here we review antiviral drugs, both approved for clinical use and under investigation, that target the influenza virus hemagglutinin and neuraminidase proteins, focusing on their mechanisms of action and the emergence of resistance to them.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据